• +1-646-491-9876
    • +91-20-67278686

    Search

    Osteoarthritis - Pipeline Review, H1 2017

    Osteoarthritis - Pipeline Review, H1 2017

    • Report Code ID: RW0001689443
    • Category Healthcare
    • No. of Pages 270
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis - Pipeline Review, H1 2017, provides an overview of the Osteoarthritis (Immunology) pipeline landscape.

    Osteoarthritis (OA) is one of the most common forms of arthritis. It is a chronic condition in which the cartilage breaks down. Symptoms of osteoarthritis include sore or stiff joints, pain that is worse after activity, bone spurs and grating sensation. Risk factors include older age, joint injuries and obesity. Treatment includes surgery, medications like non-steroidal anti-inflammatory drugs (NSAIDs) and exercise.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Osteoarthritis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Osteoarthritis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Osteoarthritis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 7, 21, 14, 46 and 14 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 5 molecules, respectively.

    Osteoarthritis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis (Immunology).
    - The pipeline guide reviews pipeline therapeutics for Osteoarthritis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Osteoarthritis (Immunology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Osteoarthritis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis (Immunology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Osteoarthritis (Immunology).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Osteoarthritis (Immunology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 7
    List of Figures 9
    Introduction 10
    Publisher Report Coverage 10
    Osteoarthritis - Overview 11
    Osteoarthritis - Therapeutics Development 12
    Pipeline Overview 12
    Pipeline by Companies 13
    Pipeline by Universities/Institutes 19
    Products under Development by Companies 20
    Products under Development by Universities/Institutes 26
    Osteoarthritis - Therapeutics Assessment 27
    Assessment by Target 27
    Assessment by Mechanism of Action 30
    Assessment by Route of Administration 33
    Assessment by Molecule Type 35
    Osteoarthritis - Companies Involved in Therapeutics Development 37
    A. Menarini Industrie Farmaceutiche Riunite Srl 37
    AbbVie Inc 37
    Abiogen Pharma SpA 38
    Ablynx NV 38
    Achelios Therapeutics Inc 39
    Addex Therapeutics Ltd 39
    Amgen Inc 40
    Amura Holdings Ltd 40
    Arcarios BV 41
    Asahi Kasei Pharma Corp 41
    Asklepios BioPharmaceutical Inc 42
    Astellas Pharma Inc 42
    Biopharm GmbH 43
    Bone Therapeutics SA 43
    Can-Fite BioPharma Ltd 44
    Cardax Inc 44
    Cellular Biomedicine Group Inc 45
    Cipla Ltd 45
    Corestem Inc 46
    Dong-A Socio Holdings Co Ltd 46
    Evgen Pharma Plc 47
    F. Hoffmann-La Roche Ltd 47
    Galapagos NV 48
    Gemphire Therapeutics Inc 48
    GeneFrontier Corp 49
    Genequine Biotherapeutics GmbH 49
    GlaxoSmithKline Plc 50
    HSRx Group 50
    InKemia IUCT Group SA 51
    International Stem Cell Corp 51
    Jeil Pharmaceutical Co Ltd 52
    Jenrin Discovery Inc 52
    K-Stemcell Co Ltd 53
    Kang Stem Biotech Co Ltd 53
    Levolta Pharmaceuticals Inc 54
    LG Chem, Ltd. 54
    Marina Biotech Inc 55
    Medivir AB 55
    Merck KGaA 56
    Mesoblast Ltd 56
    Mor Research Application Ltd 57
    NicOx SA 57
    Nordic Bioscience A/S 58
    Novartis AG 58
    NovelMed Therapeutics Inc 59
    Omeros Corp 59
    Ono Pharmaceutical Co Ltd 60
    OrthoCyte Corp 60
    Osteologix Holdings Plc 61
    Pfizer Inc 61
    Pharmalink AB 62
    Philogen SpA 62
    PhytoHealth Corp 63
    PLx Pharma Inc 63
    ProteoThera Inc 64
    Regeneus Ltd 64
    Regulaxis SAS 65
    Rottapharm Biotech Srl 65
    Samumed LLC 66
    Seikagaku Corp 66
    Stelis Biopharma Pvt Ltd 67
    Takeda Pharmaceutical Company Ltd 67
    TissueGene Inc 68
    Yooyoung Pharmaceutical Co Ltd 68
    Yuhan Corp 69
    Yungjin Pharm Co Ltd 69
    Zimmer Biomet Holdings Inc 70
    Osteoarthritis - Drug Profiles 71
    (clodronate disodium + hyaluronic acid) - Drug Profile 71
    (methylprednisolone + zoledronic acid) - Drug Profile 72
    4-P004 - Drug Profile 74
    ABT-981 - Drug Profile 75
    ALLO-ASC - Drug Profile 76
    AlloJoin - Drug Profile 78
    AM-3701 - Drug Profile 79
    AM-3876 - Drug Profile 80
    Anatabine - Drug Profile 81
    Antibody for Osteoarthritis - Drug Profile 84
    Antibody to Inhibit TGF-Beta 1 for Osteoarthritis - Drug Profile 85
    apocynin + paeonol - Drug Profile 86
    ARC-118 - Drug Profile 87
    AS-001 - Drug Profile 88
    BNP-OA - Drug Profile 89
    CDX-085 - Drug Profile 90
    celecoxib - Drug Profile 93
    Cell Therapy for Osteoarthritis - Drug Profile 94
    Chondrostem - Drug Profile 95
    clodronate disodium - Drug Profile 96
    CMX-020 - Drug Profile 97
    CR-8357 - Drug Profile 98
    CRB-0017 - Drug Profile 99
    CS-30MS02 - Drug Profile 100
    DA-5202 - Drug Profile 101
    denosumab - Drug Profile 102
    DIS-BIO-EPS - Drug Profile 112
    DNX-314 - Drug Profile 113
    Drug for Bone Diseases and Osteoarthritis - Drug Profile 114
    Drug for Osteoarthritis - Drug Profile 115
    Drug for Osteoarthritis - Drug Profile 116
    Drugs to Modulate Bone Morphogenetic Protein for Osteoarthritis and Fracture - Drug Profile 117
    Drugs to Modulate PPAR-Delta for Metabolic and Musculoskeletal Disorders - Drug Profile 118
    fasitibant chloride - Drug Profile 119
    gemcabene calcium - Drug Profile 120
    GFC-301 - Drug Profile 124
    GLPG-1972 - Drug Profile 125
    GQ-203 - Drug Profile 126
    GQ-303 - Drug Profile 127
    GSK-2394002 - Drug Profile 128
    JD-4000 Series - Drug Profile 129
    Jointstem - Drug Profile 130
    JTA-004 - Drug Profile 132
    Kartogenin - Drug Profile 133
    KBP-056 - Drug Profile 134
    ketoprofen - Drug Profile 135
    LEVI-04 - Drug Profile 137
    LH-021 - Drug Profile 138
    LNA-043 - Drug Profile 139
    MIV-711 - Drug Profile 140
    Monoclonal Antibodies for Oncology, Inflammation and Osteoarthritis - Drug Profile 143
    Monoclonal Antibody Conjugates for Osteoarthritis - Drug Profile 144
    Monoclonal Antibody for Osteoarthritis - Drug Profile 145
    MPC-75IA - Drug Profile 146
    naproxcinod - Drug Profile 147
    NBS-101 - Drug Profile 150
    NStride APS - Drug Profile 152
    ONO-4474 - Drug Profile 153
    OTXCP-03 - Drug Profile 154
    OTXCP-07 - Drug Profile 155
    PF-152 - Drug Profile 156
    PHDC-02 - Drug Profile 157
    piclidenoson - Drug Profile 158
    PL-1100 - Drug Profile 167
    PN-6047 - Drug Profile 168
    PRO-1 - Drug Profile 169
    Progenza - Drug Profile 170
    Protein for Osteoarthritis and Asthma - Drug Profile 172
    Proteins for Rheumatoid Arthritis and Osteoarthritis - Drug Profile 173
    PRX-167700 - Drug Profile 174
    Recombinant Protein for Osteoarthritis - Drug Profile 176
    Recombinant Protein to Agonize ALK and BMP Receptors for Alport Syndrome, Kidney Diseases, Metabolic Disorders and Osteoarthritis - Drug Profile 177
    Recombinant Protein to Agonize IGF-1 Receptor for Osteoarthritis - Drug Profile 179
    Recombinant Protein to Agonize IL-4 and IL-10 Receptors for Osteoarthritis and CNS - Drug Profile 180
    Reg-O3 - Drug Profile 181
    ReJoin - Drug Profile 182
    salmon calcitonin - Drug Profile 186
    SBL-005 - Drug Profile 188
    SFX-01 - Drug Profile 189
    SI-613 - Drug Profile 192
    SM-04690 - Drug Profile 193
    Small Molecule for Degenerative Arthritis - Drug Profile 196
    Small Molecule for Osteoarthritis - Drug Profile 197
    Small Molecule for Osteoarthritis - Drug Profile 198
    Small Molecule for Osteoarthritis - Drug Profile 199
    Small Molecule to Agonize A2A for Immunology, Hematological and Neurological Disorders - Drug Profile 200
    Small Molecule to Target GPR22 for Anxiety, Cardiovascular Diseases and Osteoarthritis - Drug Profile 201
    Small Molecules for Metabolic and Musculoskeletal Disorders - Drug Profile 202
    Small Molecules for Musculoskeletal and Metabolic Disorders - Drug Profile 203
    Small Molecules for Osteoarthritis - Drug Profile 204
    Small Molecules for Osteoarthritis - Drug Profile 205
    Small Molecules to Inhibit ADAMTS-5 for Osteoarthritis - Drug Profile 206
    Small Molecules to Inhibit iNOS for Osteoarthritis - Drug Profile 207
    Small Molecules to Inhibit MMP-13 for Osteoarthritis - Drug Profile 208
    sprifermin - Drug Profile 209
    Stem Cell Therapy for Articular Cartilage Lesions and Osteoarthritis - Drug Profile 211
    Stem Cell Therapy for Autoimmune Diseases - Drug Profile 212
    Stem Cell Therapy for CNS Disorders, Rheumatoid Arthritis, Osteoarthritis, Bronchopulmonary Dysplasia and Heart Failure - Drug Profile 214
    Stem Cell Therapy for Diabetes Mellitus, Acute Liver Failure, Osteoarthritis and Neurodegenerative Diseases - Drug Profile 215
    Stem Cell Therapy for Osteoarthritis and Rheumatoid Arthritis - Drug Profile 216
    Stem Cell Therapy for Osteoarthritis, Atherosclerosis and Arteriosclerosis Obliterans - Drug Profile 217
    Stempeucel - Drug Profile 218
    tonogenchoncel-L - Drug Profile 221
    TPX-100 - Drug Profile 224
    TRBN-0224 - Drug Profile 226
    UGP-302 - Drug Profile 228
    VA-694 - Drug Profile 230
    X-0002 - Drug Profile 231
    XT-101 - Drug Profile 233
    XT-150 - Drug Profile 234
    YH-14619 - Drug Profile 235
    YRA-1909 - Drug Profile 236
    YY-1201 - Drug Profile 237
    YYD-302 - Drug Profile 238
    Osteoarthritis - Dormant Projects 239
    Osteoarthritis - Discontinued Products 246
    Osteoarthritis - Product Development Milestones 248
    Featured News & Press Releases 248
    Appendix 261
    Methodology 261
    Coverage 261
    Secondary Research 261
    Primary Research 261
    Expert Panel Validation 261
    Contact Us 261
    Disclaimer 262

    List of Tables

    Number of Products under Development for Osteoarthritis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Products under Development by Companies, H1 2017 (Contd..2), H1 2017
    Products under Development by Companies, H1 2017 (Contd..3), H1 2017
    Products under Development by Companies, H1 2017 (Contd..4), H1 2017
    Products under Development by Companies, H1 2017 (Contd..5), H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Osteoarthritis - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2017
    Osteoarthritis - Pipeline by AbbVie Inc, H1 2017
    Osteoarthritis - Pipeline by Abiogen Pharma SpA, H1 2017
    Osteoarthritis - Pipeline by Ablynx NV, H1 2017
    Osteoarthritis - Pipeline by Achelios Therapeutics Inc, H1 2017
    Osteoarthritis - Pipeline by Addex Therapeutics Ltd, H1 2017
    Osteoarthritis - Pipeline by Amgen Inc, H1 2017
    Osteoarthritis - Pipeline by Amura Holdings Ltd, H1 2017
    Osteoarthritis - Pipeline by Arcarios BV, H1 2017
    Osteoarthritis - Pipeline by Asahi Kasei Pharma Corp, H1 2017
    Osteoarthritis - Pipeline by Asklepios BioPharmaceutical Inc, H1 2017
    Osteoarthritis - Pipeline by Astellas Pharma Inc, H1 2017
    Osteoarthritis - Pipeline by Biopharm GmbH, H1 2017
    Osteoarthritis - Pipeline by Bone Therapeutics SA, H1 2017
    Osteoarthritis - Pipeline by Can-Fite BioPharma Ltd, H1 2017
    Osteoarthritis - Pipeline by Cardax Inc, H1 2017
    Osteoarthritis - Pipeline by Cellular Biomedicine Group Inc, H1 2017
    Osteoarthritis - Pipeline by Cipla Ltd, H1 2017
    Osteoarthritis - Pipeline by Corestem Inc, H1 2017
    Osteoarthritis - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017
    Osteoarthritis - Pipeline by Evgen Pharma Plc, H1 2017
    Osteoarthritis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Osteoarthritis - Pipeline by Galapagos NV, H1 2017
    Osteoarthritis - Pipeline by Gemphire Therapeutics Inc, H1 2017
    Osteoarthritis - Pipeline by GeneFrontier Corp, H1 2017
    Osteoarthritis - Pipeline by Genequine Biotherapeutics GmbH, H1 2017
    Osteoarthritis - Pipeline by GlaxoSmithKline Plc, H1 2017
    Osteoarthritis - Pipeline by HSRx Group, H1 2017
    Osteoarthritis - Pipeline by InKemia IUCT Group SA, H1 2017
    Osteoarthritis - Pipeline by International Stem Cell Corp, H1 2017
    Osteoarthritis - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017
    Osteoarthritis - Pipeline by Jenrin Discovery Inc, H1 2017
    Osteoarthritis - Pipeline by K-Stemcell Co Ltd, H1 2017
    Osteoarthritis - Pipeline by Kang Stem Biotech Co Ltd, H1 2017
    Osteoarthritis - Pipeline by Levolta Pharmaceuticals Inc, H1 2017
    Osteoarthritis - Pipeline by LG Chem, Ltd., H1 2017
    Osteoarthritis - Pipeline by Marina Biotech Inc, H1 2017
    Osteoarthritis - Pipeline by Medivir AB, H1 2017
    Osteoarthritis - Pipeline by Merck KGaA, H1 2017
    Osteoarthritis - Pipeline by Mesoblast Ltd, H1 2017
    Osteoarthritis - Pipeline by Mor Research Application Ltd, H1 2017
    Osteoarthritis - Pipeline by NicOx SA, H1 2017
    Osteoarthritis - Pipeline by Nordic Bioscience A/S, H1 2017
    Osteoarthritis - Pipeline by Novartis AG, H1 2017
    Osteoarthritis - Pipeline by NovelMed Therapeutics Inc, H1 2017
    Osteoarthritis - Pipeline by Omeros Corp, H1 2017
    Osteoarthritis - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
    Osteoarthritis - Pipeline by OrthoCyte Corp, H1 2017
    Osteoarthritis - Pipeline by Osteologix Holdings Plc, H1 2017
    Osteoarthritis - Pipeline by Pfizer Inc, H1 2017
    Osteoarthritis - Pipeline by Pharmalink AB, H1 2017
    Osteoarthritis - Pipeline by Philogen SpA, H1 2017
    Osteoarthritis - Pipeline by PhytoHealth Corp, H1 2017
    Osteoarthritis - Pipeline by PLx Pharma Inc, H1 2017
    Osteoarthritis - Pipeline by ProteoThera Inc, H1 2017
    Osteoarthritis - Pipeline by Regeneus Ltd, H1 2017
    Osteoarthritis - Pipeline by Regulaxis SAS, H1 2017
    Osteoarthritis - Pipeline by Rottapharm Biotech Srl, H1 2017
    Osteoarthritis - Pipeline by Samumed LLC, H1 2017
    Osteoarthritis - Pipeline by Seikagaku Corp, H1 2017
    Osteoarthritis - Pipeline by Stelis Biopharma Pvt Ltd, H1 2017
    Osteoarthritis - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
    Osteoarthritis - Pipeline by TissueGene Inc, H1 2017
    Osteoarthritis - Pipeline by Yooyoung Pharmaceutical Co Ltd, H1 2017
    Osteoarthritis - Pipeline by Yuhan Corp, H1 2017
    Osteoarthritis - Pipeline by Yungjin Pharm Co Ltd, H1 2017
    Osteoarthritis - Pipeline by Zimmer Biomet Holdings Inc, H1 2017
    Osteoarthritis - Dormant Projects, H1 2017
    Osteoarthritis - Dormant Projects, H1 2017 (Contd..1), H1 2017
    Osteoarthritis - Dormant Projects, H1 2017 (Contd..2), H1 2017
    Osteoarthritis - Dormant Projects, H1 2017 (Contd..3), H1 2017
    Osteoarthritis - Dormant Projects, H1 2017 (Contd..4), H1 2017
    Osteoarthritis - Dormant Projects, H1 2017 (Contd..5), H1 2017
    Osteoarthritis - Discontinued Products, H1 2017
    Osteoarthritis - Discontinued Products, H1 2017 (Contd..1), H1 2017

    List of Figures

    Number of Products under Development for Osteoarthritis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    A. Menarini Industrie Farmaceutiche Riunite Srl
    AbbVie Inc
    Abiogen Pharma SpA
    Ablynx NV
    Achelios Therapeutics Inc
    Addex Therapeutics Ltd
    Amgen Inc
    Amura Holdings Ltd
    Arcarios BV
    Asahi Kasei Pharma Corp
    Asklepios BioPharmaceutical Inc
    Astellas Pharma Inc
    Biopharm GmbH
    Bone Therapeutics SA
    Can-Fite BioPharma Ltd
    Cardax Inc
    Cellular Biomedicine Group Inc
    Cipla Ltd
    Corestem Inc
    Dong-A Socio Holdings Co Ltd
    Evgen Pharma Plc
    F. Hoffmann-La Roche Ltd
    Galapagos NV
    Gemphire Therapeutics Inc
    GeneFrontier Corp
    Genequine Biotherapeutics GmbH
    GlaxoSmithKline Plc
    HSRx Group
    InKemia IUCT Group SA
    International Stem Cell Corp
    Jeil Pharmaceutical Co Ltd
    Jenrin Discovery Inc
    K-Stemcell Co Ltd
    Kang Stem Biotech Co Ltd
    Levolta Pharmaceuticals Inc
    LG Chem, Ltd.
    Marina Biotech Inc
    Medivir AB
    Merck KGaA
    Mesoblast Ltd
    Mor Research Application Ltd
    NicOx SA
    Nordic Bioscience A/S
    Novartis AG
    NovelMed Therapeutics Inc
    Omeros Corp
    Ono Pharmaceutical Co Ltd
    OrthoCyte Corp
    Osteologix Holdings Plc
    Pfizer Inc
    Pharmalink AB
    Philogen SpA
    PhytoHealth Corp
    PLx Pharma Inc
    ProteoThera Inc
    Regeneus Ltd
    Regulaxis SAS
    Rottapharm Biotech Srl
    Samumed LLC
    Seikagaku Corp
    Stelis Biopharma Pvt Ltd
    Takeda Pharmaceutical Company Ltd
    TissueGene Inc
    Yooyoung Pharmaceutical Co Ltd
    Yuhan Corp
    Yungjin Pharm Co Ltd
    Zimmer Biomet Holdings Inc

    Request for Sample

    Report Url http://www.reportsweb.com//osteoarthritis-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//osteoarthritis-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//osteoarthritis-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments